Humoral Immune Response to COVID-19 Vaccination in Psoriasis Patients on Biologic Therapy Is Impaired Compared to Healthy Controls
TLDR Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
The study investigated the humoral immune response to COVID-19 vaccination in psoriasis patients undergoing biologic therapy compared to healthy controls. Blood samples were collected 4 to 8 weeks after the second vaccination dose, and IgG and IgA antibody titers were measured using ELISA analysis. The psoriasis group included patients treated with IL-17 inhibitors, IL-23 inhibitors, and TNF alpha inhibitors. Results indicated that psoriasis patients on biologic therapy had significantly lower anti-COVID-19 IgG antibody titers compared to healthy controls. These findings suggest that vaccination recommendations may need adjustment for immunosuppressed patients.
